Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03275350 · ClinicalTrials.gov registry record · Phase 2

Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up

A Phase 2 study, sponsored by Oregon Health and Science University.

Completed
Registry status
Phase 2
Development phase
114
Enrollment target

NCT03275350: Completed Phase 2 study, sponsored by Oregon Health and Science University.

NCT03275350 is a Phase 2 study that has completed, run by Oregon Health and Science University. The registered enrollment target is 114 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03275350, a Phase 2 study, has completed, sponsored by Oregon Health and Science University.

COMPLETED
Registry status
Phase 2
Development phase
114 participants
Enrollment target

Study Summary

The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.

Primary Outcome

HIV-1 RNA \<200 copies/ml

Interventions

  • OTHER Treatment as usual
  • DRUG Naltrexone Injectable Suspension

Trial Details

FieldValue
Enrollment Target 114 participants
Start Date 2018-02-05
Est. Completion 2019-11-08
Phase Phase 2

What the finished NCT03275350 record still lists

NCT03275350 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).

The record links to 0 conditions, and to 2 interventions - of which Treatment as usual is the first listed.

NCT03275350 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03275350 about?

NCT03275350 is a clinical study titled "Comparing Treatments for HIV-Infected Opioid Users in an Integrated Care Effectiveness Study (CHOICES) Scale-Up". The Primary Objective of this study is to compare the effectiveness of HIV clinic-based extended-release Naltrexone (XR-NTX) in decreasing substance use and increasing HIV viral suppression in HIV-infected participants with opioid use disorder to Treatment as Usual in this population.

What is the current status of trial NCT03275350?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 114 participants. The study started on 2018-02-05. Estimated completion is 2019-11-08.

What interventions are being tested in trial NCT03275350?

The interventions under investigation include: Treatment as usual (OTHER), Naltrexone Injectable Suspension (DRUG).

Who is sponsoring clinical trial NCT03275350?

This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT03275350's enrollment target sits among peer trials

114 627th of 2000 higher than 1,370 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04522791 · 114 participants · Phase 2

    Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)

  • NCT04875052 · 114 participants · NA

    Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury

  • NCT05100342 · 114 participants

    Prospective Validation of a Points Score System Predicting 30-day Survival

  • NCT05224089 · 114 participants · Phase 4

    Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03275350, the US trial registry maintained by the National Library of Medicine. NCT03275350 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.